ProFibrix, a Netherlands-based developer of innovative products for hemostasis and regenerative medicine, closed a $11m series B investment in an operation led by new investor Gilde Healthcare Partners, an European life sciences investor and existing Index Ventures.
ProFibrix, founded in 2004 and headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, USA, will apply the proceeds of the financing to develop Fibrocaps, a new tissue sealant that stops acute and severe bleeding during surgery or in connection with trauma injury, and other pipeline products.
FinSMEs
26/08/2009